|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,152.00 JPY | +0.58% |
|
+0.23% | +2.82% |
| 06-30 | Trump's push for the world's lowest drug prices hits snag with mid-sized companies | RE |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| Market Cap | 3,855B 23.9B 20.9B 19.2B 17.9B 33.95B 2,276B 34.47B 231B 89.63B 1,119B 89.73B 87.8B | P/E 2027 * |
11.2x | P/E 2028 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3,779B 23.43B 20.48B 18.82B 17.54B 33.28B 2,231B 33.78B 226B 87.84B 1,097B 87.94B 86.05B | EV / Sales 2027 * |
1.68x | EV / Sales 2028 * | 1.67x |
| Free-Float |
98.88% | Yield 2027 * |
3.74% | Yield 2028 * | 3.85% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +0.58% | ||
| 1 week | +0.23% | ||
| Current month | -1.06% | ||
| 1 month | -0.81% | ||
| 3 months | -17.25% | ||
| 6 months | +2.82% | ||
| Current year | +2.82% |
| 1 week | 2,105 |  | 2,204 |
| 1 month | 2,041 | | 2,204 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.58% | +0.23% | +54.65% | +0.14% | 23.82B | |
| +3.45% | +7.65% | +55.77% | +158.84% | 1,082B | |
| -1.16% | +7.42% | +69.09% | +58.92% | 633B | |
| -0.77% | +7.37% | +36.87% | +93.77% | 461B | |
| -0.35% | +1.58% | +30.95% | +24.53% | 339B | |
| -0.56% | +0.96% | +41.67% | +39.35% | 301B | |
| -0.08% | +1.52% | +29.96% | +42.13% | 292B | |
| -1.54% | +2.81% | -25.35% | -39.61% | 225B | |
| +3.55% | +6.05% | +26.04% | +68.52% | 202B | |
| +0.40% | +6.00% | +17.72% | +70.33% | 163B | |
| Average | +1.03% | +4.26% | +33.74% | +51.69% | 372.35B | |
| Weighted average by Cap. | +1.03% | +5.38% | +42.08% | +80.94% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,250B 13.95B 12.2B 11.21B 10.45B 19.82B 1,328B 20.12B 135B 52.31B 653B 52.37B 51.25B | 2,072B 12.85B 11.23B 10.32B 9.62B 18.24B 1,223B 18.52B 124B 48.16B 601B 48.22B 47.18B |
| Net income | 345B 2.14B 1.87B 1.72B 1.6B 3.03B 203B 3.08B 20.61B 8.01B 100B 8.02B 7.85B | 325B 2.01B 1.76B 1.62B 1.51B 2.86B 192B 2.9B 19.42B 7.55B 94.24B 7.56B 7.4B |
| Net Debt | -76.78B -476M -416M -382M -357M -676M -45.33B -686M -4.59B -1.79B -22.28B -1.79B -1.75B | -391B -2.43B -2.12B -1.95B -1.82B -3.45B -231B -3.5B -23.4B -9.1B -114B -9.11B -8.91B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/07/26 | ¥2,152.00 | +0.58% | 5,173,500 |
| 02/07/26 | ¥2,139.50 | +0.94% | 6,188,700 |
| 01/07/26 | ¥2,119.50 | -2.55% | 5,055,800 |
| 30/06/26 | ¥2,175.00 | +0.18% | 9,968,900 |
| 29/06/26 | ¥2,171.00 | +1.21% | 10,716,900 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
